ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2024

Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China.

Shouzheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.